Reolysin: Interim Phase II data

Interim data from the open-label, U.S. Phase II REO 014 trial in 36 evaluable patients showed that IV Reolysin produced 15 cases of stable disease >16 weeks, including 5 >24 weeks and 1 >80 weeks. Reo...